Difference between revisions of "Bevacizumab (Avastin)"
Jump to navigation
Jump to search
(Information about counterfeit Bevacizumab (Avastin)) |
|||
| Line 5: | Line 5: | ||
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the package insert<ref name="insert"></ref>. | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the package insert<ref name="insert"></ref>. | ||
| + | |||
| + | ==Information about counterfeit Bevacizumab (Avastin)== | ||
| + | *[http://www.fda.gov/drugs/drugsafety/ucm291960.htm FDA's 2/14/2012 statement about counterfeit Avastin in U.S.] | ||
| + | *[http://www.gene.com/gene/news/press-releases/press_statements/ps_021412.html Genentech's 2/14/2012 statement on counterfeit drug labeled as Avastin (Bevacizumab) in the United States] - contains pictures of authentic and counterfeit product | ||
| + | *[http://www.genentechaccesssolutions.com/portal/site/AS/menuitem.7ef3b8542d7c63460313edacd79c23a0/?vgnextoid=359169cc87727210VgnVCM1000007dc9320aRCRD&vgnextchannel=268c57e77eb07210VgnVCM1000007dc9320aRCRD Authorized specialty distributors, wholesalers and specialty pharmacies for Bevacizumab (Avastin)] | ||
==Patient drug information== | ==Patient drug information== | ||
Revision as of 18:51, 19 April 2012
General information
Class/mechanism: Monoclonal antibody that inhibits angiogenesis by binding VEGF and preventing the interaction of VEGF with its receptors (Flt-1 and KDR) on the surface of endothelial cells.[1][2]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the package insert[1].
Information about counterfeit Bevacizumab (Avastin)
- FDA's 2/14/2012 statement about counterfeit Avastin in U.S.
- Genentech's 2/14/2012 statement on counterfeit drug labeled as Avastin (Bevacizumab) in the United States - contains pictures of authentic and counterfeit product
- Authorized specialty distributors, wholesalers and specialty pharmacies for Bevacizumab (Avastin)
Patient drug information
- Bevacizumab (Avastin) patient drug information (Chemocare)[3]
- Bevacizumab (Avastin) patient drug information (UpToDate)[4]